GLENMARK

Semaglutide Launch (Big Trigger)

💊 Semaglutide Launch (Big Trigger) Launched generic semaglutide (GLP-1 drug) in India Used for: Diabetes Weight loss 👉 Impact: Entry into high-growth obesity/diabetes segment Huge market opportunity going forward 🇺🇸 US FDA Approvals Multiple FDA approvals in 2026: Respiratory drugs Hormone-related products Strengthening presence in US generics market 🧪 Specialty & Innovation Push Increasing focus on: Specialty pharma Oncology pipeline Earlier $700M+ licensing deal for cancer drug continues to support long-term outlook 📈 Financial Performance Recent results show: ~15% revenue growth YoY Strong India business performance Margins improving due to: Better product mix Specialty portfolio 🌍 Global Business Expansion Active launches in: US Canada Other regulated markets Strengthening presence in: Respiratory Dermatology Oncology ⚠️ Key Concerns Stock trading at premium valuation after sharp rally Risk of profit booking in short term Regulatory risks (USFDA observations historically)